Market closedNon-fractional
Metagenomi/MGX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Metagenomi
Metagenomi Inc is a genetic medicines company committed to developing curative therapeutics for patients using its proprietary, comprehensive metagenomics-derived genome editing toolbox. Genetic diseases are caused by a diverse set of mutations that have been largely inaccessible by genome engineering approaches to date. The genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems (including prime editing systems and clustered regularly interspaced short palindromic repeat (CRISPR)-associated transposases (CASTs).
Ticker
MGX
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
Emeryville, United States
Employees
237
Website
www.metagenomi.co
Metagenomi Metrics
BasicAdvanced
$156M
Market cap
-
P/E ratio
-$9.86
EPS
-
Beta
-
Dividend rate
Price and volume
Market cap
$156M
Financial strength
Current ratio
4.747
Quick ratio
4.679
Long term debt to equity
15.847
Total debt to equity
17.437
Management effectiveness
Return on equity (TTM)
-28.24%
Valuation
Price to revenue (TTM)
0.69
Price to book
0.57
Price to tangible book (TTM)
0.57
Price to free cash flow (TTM)
-0.301
Growth
Revenue change (TTM)
109.93%
Earnings per share change (TTM)
-45.84%
What the Analysts think about Metagenomi
Analyst Ratings
Majority rating from 7 analysts.
Metagenomi Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$12M
0.00%
Net income
-$19M
-3.03%
Profit margin
-156.09%
-3.03%
Metagenomi Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q1 24
Q2 24
Actual
-$1.19
-
Expected
-$0.78
-$0.65
Surprise
53.22%
-
Metagenomi News
AllArticlesVideos
Metagenomi to Present at the 2024 Jefferies Global Healthcare Conference
GlobeNewsWire·1 month ago
Metagenomi Presents Data at Scientific Conferences and First Quarter 2024 Financial Results
GlobeNewsWire·2 months ago
Metagenomi to regain full development rights to its wholly-owned base editing and RIGS systems
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Metagenomi stock?
Metagenomi (MGX) has a market cap of $156M as of July 06, 2024.
What is the P/E ratio for Metagenomi stock?
The price to earnings (P/E) ratio for Metagenomi (MGX) stock is 0 as of July 06, 2024.
Does Metagenomi stock pay dividends?
No, Metagenomi (MGX) stock does not pay dividends to its shareholders as of July 06, 2024.
When is the next Metagenomi dividend payment date?
Metagenomi (MGX) stock does not pay dividends to its shareholders.
What is the beta indicator for Metagenomi?
Metagenomi (MGX) does not currently have a Beta indicator.
Buy or sell Metagenomi stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.